Home Page
HOME PAGE CLINICAL SERVICES RESEARCH STUDIES RESIDENCY PROGRAM
  

Zonisamide versus Placebo in the Treatment of Alcohol Dependence

Description:
This is a pilot study designed to examine the potential efficacy and tolerability of zonisamide compared to placebo for the treatment of alcoholism. Zonisamide is an antiepileptic medication which has similar clinical and pharmacologic effects to topiramate, a medication that has demonstrated efficacy in a randomized clinical trial for treatment of alcoholism. Because zonisamide is potentially better tolerated and easier to titrate in the outpatient setting than topiramate, it may offer important clinical advantages in the treatment of alcoholism.

This is small a 12-week placebo-controlled pilot study examining tolerability and potential efficacy in anticipation of a larger, placebo-controlled trial of zonisamide for treatment of alcohol dependence. It is a randomized, double-blind trial of zonisamide versus placebo at flexible dosages of 100-500mg/day in alcoholics receiving ambulatory psychosocial treatment. Participants will take part in six individual Cognitive-Behavioral based therapy sessions, which are focused on learning coping skills. Participants must endorse a goal of either cutting down their drinking to non-hazardous levels, or abstinence.

More Info:
ClinicalTrials.gov Protocol Record

Mailing Address:
Kristen Tremblay, MC2103
University of Connecticut Health Center
263 Farmington Avenue
Farmington, CT 06030-2103

Primary Investigator:
Albert J. Arias, M.D.

UConn       UCHC      People
SITE MAP         UCONN HOME         UCHC HOME        TEXT-ONLY © University of Connecticut
Disclaimers, Privacy, & Copyright
Contact      Maps & Directions